JYJialei Yang

Jialei Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jialei Yang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Miao He

    Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    4 shared publications
  • Shipo Wu

    National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China

    4 shared publications
  • Xiaoyu Lin

    Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    3 shared publications
  • Yongjun Wang

    Department of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China

    3 shared publications
  • Xia Meng

    China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Xingquan Zhao

    Department of Neurology, Beijing Tiantan Hospital, Capital Medical University

    2 shared publications

Latest Publications

  • Open Access

    Extracellular Vesicle-Mediated Delivery of Mitochondrial Circular RNA MTCO2 Protects against Cerebral Ischemia by Modulating mPTP-Dependent Ferroptosis

    by Jialei Yang, Shipo Wu, Miao He

    Ischemic stroke remains a major cause of mortality and long-term disability, with few effective neuroprotective treatments currently available. Ferroptosis, an iron-dependent form of regulated cell death marked by lipid peroxidation, is increasingly recognized as a driver of neuronal damage. However, the mitochondrial mechanisms linking ischemia to ferroptosis remain poorly defined. Here, we identify circMTCO2, a mitochondria-encoded circular RNA (circRNA), as a novel endogenous modulator of neuronal ferroptosis. circMTCO2 expression is dynamically down-regulated following cerebral ischemia/reperfusion in vitro and in vivo. Mechanistically, circMTCO2 interacts with adenine nucleotide translocase 1 (ANT1), a key regulator associated with the mitochondrial permeability transition pore (mPTP), thereby inhibiting mPTP opening and suppressing mitochondrial reactive oxygen species release. Disruption of the binding site abolishes circMTCO2–ANT1 interaction and eliminates the protective effects of circMTCO2. To restore and enhance this intrinsic defense mechanism, we developed a dual-targeting extracellular vesicle system (RVG-EV mt-RNA ) capable of delivering circMTCO2 specifically to neuronal mitochondria. Systemic administration of RVG-EV mt-RNA decreased infarct volume, attenuated ferroptosis-associated injury, and improved neurological function in a mouse model of ischemic stroke, without inducing systemic toxicity. These findings establish circMTCO2 as a previously unrecognized mitochondrial circRNA that regulates ferroptosis by modulating mPTP activity and provide a proof of concept that organ-to-organelle circRNA delivery can be leveraged as a precision neuroprotective strategy for ischemic stroke.


  • PCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial

    by Xiaoyu Lin, Cang Guo, Xia Meng, Xingquan Zhao, Hao Li, Yongjun Wang, Jialei Yang

    BACKGROUND: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain. METHODS: CHANCE-2 (Ticagrelor or Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles. Patients received ticagrelor-aspirin or clopidogrel-aspirin. This secondary analysis included patients with PCIS, stratified into low- (≤15), intermediate- (16–20), and high-risk (≥21) groups based on PCISOS. The primary outcome was 90-day stroke recurrence. Outcomes were analyzed using Cox and logistic regression models, adjusting for significantly imbalanced baseline covariates relevant to each comparison. RESULTS: Among 1379 patients with PCIS (median age, 64.0 [56.6–70.7] years; 67.4% male), 90-day stroke recurrence occurred in 6.0%, 8.2%, and 18.5% of the low-, intermediate-, and high-risk PCISOS groups, respectively ( P P trend =0.008). Similar associations were observed for modified Rankin Scale score of 2 to 6 outcomes (adjusted odds ratio for intermediate-risk, 2.21 [95% CI, 1.28–3.84]; high-risk, 3.53 [95% CI, 1.42–8.74]; P trend P interaction =0.03). Favorable outcome (modified Rankin Scale score of 0–1) was more common in patients with PCISOS ≤15 than in those with National Institutes of Health Stroke Scale score ≤3 ( P =0.02). CONCLUSIONS: PCISOS provides effective risk stratification in minor PCIS, identifying subgroups with heterogeneous outcome risks and differential response to ticagrelor-aspirin. Patients with PCISOS ≥21, a high-risk subgroup within National Institutes of Health Stroke Scale–defined minor strokes, remain underexplored and may benefit from tailored strategies in future trials. A threshold of PCISOS ≤15 may more accurately define truly low-risk patients than National Institutes of Health Stroke Scale score ≤3, thereby improving trial efficiency and advancing precision in PCIS research. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04078737.


  • Open Access

    Engineered Exosome‐Based Senolytic Therapy Alleviates Stroke by Targeting p21+CD86+ Microglia

    by Jialei Yang, Shipo Wu, Miao He

    Stroke remains the leading cause of neurological mortality and disability worldwide, with post‐stroke inflammation significantly hindering neural repair. Despite its critical impact, mechanism‐based therapeutic strategies are scarce. In this study, we uncovered a critically important yet previously unexamined cell population, p21+CD86+ microglia, which accumulated in ischemic region. Unexpectedly, we discovered that p21 interacted with C/EBPβ, driving C/EBPβ‐dependent transcription and upregulating key pro‐inflammatory factors such as Il6, Il1β, Cxcl2, and Cxcl10. To specifically target and eliminate these pathogenic p21+CD86+ microglia, we engineered exosomes with a peptide that selectively binds CD86+ microglia and loaded them with the senolytic Quercetin. Furthermore, we developed an optimized, stable Que@micro‐Exo therapeutic formulation. Systemic administration of Que@micro‐Exo robustly reduced p21+CD86+ microglia and suppressed their pro‐inflammatory phenotype. Notably, functional analyses revealed that Que@micro‐Exo treatment mitigated blood‐brain barrier disruption, promoted beneficial microglial polarization, decreased neutrophil infiltration, and significantly enhanced functional recovery following cerebral ischemia, all with a favorable safety profile. Our preclinical findings lay the foundation for targeting p21+CD86+ microglia as a novel therapeutic strategy, highlighting the potential of exosome‐based senolytic anti‐inflammatory therapy for stroke and other central nervous system disorders.


  • Derivation and Validation of a Scoring System for Predicting Poor Outcome After Posterior Circulation Ischemic Stroke in China

    by Jialei Yang, Xiaoyu Lin, Anxin Wang, Xia Meng, Xingquan Zhao, Jing Jing, Yijun Zhang, Hao Li, Yongjun Wang

    Guidelines for posterior circulation ischemic stroke (PCIS) treatment are lacking and outcome prediction is crucial for patients and clinicians. We aimed to develop and validate a prognostic score to predict the poor outcome for patients with PCIS. The score was developed from a prospective derivation cohort named the Third China National Stroke Registry (August 2015-March 2018) and validated in a spatiotemporal independent validation cohort (December 2017-March 2023) in China. Patients with PCIS with acute infarctions defined as hyperintense lesions on diffusion-weighted imaging were included in this study. The poor outcome was measured as modified Rankin scale (mRS) score 3-6 at 3 months after PCIS. Multivariable logistic regression analysis was used to identify predictors for poor outcome. The prognostic score, namely PCIS Outcome Score (PCISOS), was developed by assigning points to variables based on their relative β-coefficients in the logistic model. The PCISOS was derived from 3,294 patients (median age 62 [interquartile range (IQR) 55-70] years; 2,250 [68.3%] men) and validated in 501 patients (median age 61 [IQR 53-68] years; 404 [80.6%] men). Among them, 384 (11.7%) and 64 (12.8%) had poor outcome 3 months after stroke in respective cohorts. Age, mRS before admission, NIH Stroke Scale on admission, ischemic stroke history, infarction distribution, basilar artery, and posterior cerebral artery stenosis or occlusion were identified as independent predictors for poor outcome and included in PCISOS. This easy-to-use integer scoring system identified a marked risk gradient between 4 risk groups. PCISOS performed better than previous scores, with an excellent discrimination (C statistic) of 0.80 (95% CI 0.77-0.83) in the derivation cohort and 0.81 (95% CI 0.77-0.84) in the validation cohort. Calibration test showed high agreement between the predicted and observed outcomes in both cohorts. PCISOS can be applied for patients with PCIS with acute infarctions to predict functional outcome at 3 months post-PCIS. This simple tool helps clinicians to identify patients with PCIS with higher risk of poor outcome and provides reliable outcome expectations for patients. This information might be used for personalized rehabilitation plan and patient selection for future clinical trials to reduce disability and mortality.